miriplatin-TAI in TACE refractory HCC

miriplatin-TAI in TACE refractory HCC - National Cancer Center Clinical Studies in HBPO group -002

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000005408

Enrollment

Registered

2011-04-08

Start date

2011-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

TACE Refractory HCC

Interventions

miriplatin

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: TACE refractory HCC

Exclusion criteria

Exclusion criteria: Child-Pugh C

Design outcomes

Primary

Measure	Time frame
Response in mRECIST	—

Countries

Japan

Contacts

Public ContactSatoshi Shiba

National Cancer Center Hospital Hepato-bilialy and pancreatic Oncology

sashiba@ncc.go.jp

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026